Abstracts tagged "IL-6"

Abstract Number: 2473 • 2017 ACR/ARHP Annual Meeting
Sirukumab Subcutaneous Dose Regimens Maintain Clinical Response over Dosing Intervals in Rheumatoid Arthritis Patients: Results from a Phase 3 Study
David M. Brooks¹, Michael Plotnick², Nicola J. Williams³, Regina Kurrasch¹, Yanli Zhuang², Debra J. Tompson³, Benjamin Hsu² and Ravi Rao³, ¹GlaxoSmithKline, Collegeville, PA, ²Janssen Research & Development, LLC, Spring House, PA, ³GlaxoSmithKline, Stevenage, Hertfordshire, United Kingdom
Background/Purpose: Sirukumab (SIR), a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, has demonstrated efficacy in rheumatoid arthritis (RA)…
Abstract Number: 969 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of Subcutaneous Tocilizumab in Early Systemic Sclerosis: Results from the Open-Label Period of a Phase 2 Randomized, Controlled Trial
Dinesh Khanna¹, Christopher Denton², Helen Spotswood³, Angelika Jahreis⁴, Jacob M. van Laar⁵, Laura Burke⁶, Celia J. F. Lin⁴, Janet E. Pope⁷, Yannick Allanore⁸, Ulf Müller-Ladner⁹, Jeffrey Siegel⁶, Daniel E. Furst¹⁰ and faSScinate Clinical Trial Investigators, ¹University of Michigan, Ann Arbor, MI, ²Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ³Roche Products Ltd., Welwyn Garden City, CA, United Kingdom, ⁴Genentech, South San Francisco, CA, ⁵University Medical Center Utrecht, Utrecht, Netherlands, ⁶Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁷University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ⁸Rheumatology, Paris Descartes University, Paris, France, ⁹Justus-Liebig-University Giessen, Department of Internal Medicine and Rheumatology, Kerckhoff-Klinik, Bad Nauheim, Germany, Bad-Nauheim, Germany, ¹⁰University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Systemic sclerosis (SSc) is a debilitating disease with few treatment options. Interleukin-6 (IL-6) appears to play a role in SSc pathogenesis (J Rheumatol 1998;25:308;…
Abstract Number: 976 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Tocilizumab in Patients with Refractory Takayasu Arteritis: Results from a Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial in Japan
Yoshikazu Nakaoka¹, Mitsuaki Isobe², Syuji Takei³, Yoshiya Tanaka⁴, Tomonori Ishii⁵, Shumpei Yokota⁶, Akira Nomura⁷, Seitaro Yoshida⁷ and Norihiro Nishimoto⁸, ¹Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan, ²Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan, ³School of Health Sciences, Faculty of Medicine, Kagoshima University, Kagoshima, Japan, ⁴University of Occupational and Environmental Health, Kitakyushu, Japan, ⁵Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, ⁶Laboratory of Pediatric Research, Medical Research Institute of Tokyo Medical School, Tokyo, Japan, ⁷Chugai Pharmaceutical Co., Ltd., Tokyo, Japan, ⁸Osaka Rheumatology Clinic, Osaka, Japan
Background/Purpose: Glucocorticoids (GC) are the mainstay of treatment options for patients (pts) with Takayasu arteritis (TAK); however, long-term GC therapy is associated with adverse events…
Abstract Number: 1560 • 2016 ACR/ARHP Annual Meeting
A Unique Immune Signature in Patients with Active Rheumatoid Arthritis but Normal C-Reactive Protein Levels: Potential for New Therapeutic Targets?
Claire Bradford¹, Rosa González-Serrano¹, Andrew Cole¹, Shashank Ramakrishnan¹, Giampiero Marra¹, Coziana Ciurtin², Elizabeth Jury¹ and Jessica Manson³, ¹Division of Medicine, Centre for Rheumatology Research, University College London, London, United Kingdom, ²Rheumatology Department, University College London, London, United Kingdom, ³Rheumatology Department, University College London Hospital, London, United Kingdom
Background/Purpose: Using musculoskeletal ultrasound (US) to assess joint erosions and disease activity in patients with seropositive rheumatoid arthritis (RA) an atypical subgroup was identified with…
Abstract Number: 1581 • 2016 ACR/ARHP Annual Meeting
The Combination of IL-6 and IL-6 Receptor Levels As a Biomarker of Response to Tocilizumab in Rheumatoid Arthritis Patients
Cesar Diaz-Torne¹, Maria A. Ortiz², Patricia Moya³, M. Victoria Hernández⁴, Delia Reina⁵, Ivan Castellvi⁶, Juan Jose De Agustin⁷, Diana De La Fuente⁸, Hector Corominas^9,10, Raimon Sanmarti¹¹, Josep Maria De Llobet Zubiaga¹ and Silvia Vidal², ¹Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, ²Institut de Recerca Sant Pau, Barcelona, Spain, ³Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, ⁵Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ⁶Rheumatology, Hospital de Sant Pau, Barcelona, Spain, ⁷Rheumatology, Hospital Baix de Llobregat, Barcelona, Spain, ⁸Rheumatology, Hospital de Viladecans, Barcelona, Spain, ⁹Rheumatology, Hospital Moises Broggi, Barcelona, Spain, ¹⁰Servei de Reumatologia, Hospital Moises Broggi, Barcelona, Spain, ¹¹Arthritis Unit. Rheumatology, Arthritis Unit. Rheumatology Department. Hospital Clínic, Barcelona, Spain
Background/Purpose: Several predictors of response to tocilizumab have been described. They include a low HAQ, high baseline CRP or NK levels and certain IL-6R polymorphisms.…
Abstract Number: 1598 • 2016 ACR/ARHP Annual Meeting
Olokizumab Treatment of Both Western and Asian Patients with Rheumatoid Arthritis Who Have Failed Anti-TNF Treatment Results in Sustained Improvements in Patient-Reported Outcomes
Mark C. Genovese¹, Patrick Durez², Roy Fleischmann³, Yoshiya Tanaka⁴, Daniel E. Furst⁵, Hisashi Yamanaka⁶, Igor Vasyutin⁷, Thangavel Kaviarasu⁸, Elena Korneva⁷, Dmitry Koloda⁷ and Tsutomu Takeuchi⁹, ¹Stanford University Medical Center, Palo Alto, CA, ²Department of Rheumatology, Université Catholique de Louvain, Brussels, Belgium, ³Medicine, University of Texas Southwestern Medical Center, Dallas, TX, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ⁵David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁶Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁷R-Pharm CJSC, Moscow, Russian Federation, ⁸Quintiles Inc, Mumbai, India, ⁹School of Medicine, Keio University, Tokyo, Japan
Background/Purpose: Rheumatoid arthritis (RA) has a high patient (pt) burden with significant impact on health-related quality of life. We report the effect of treatment with…
Abstract Number: 1607 • 2016 ACR/ARHP Annual Meeting
The Development of a New Anti–Interleukin 6 Blocker for Rheumatoid Arthritis Patients
Alan Glicklich¹, Paul Grayson¹, Christophe Blanchetot², Qing Zhou³ and Anke Kretz-Rommel¹, ¹Bird Rock Bio, Inc, La Jolla, CA, ²Argenx, Ghent, Belgium, ³Genor BioPharma, Shanghai, China
Background/Purpose: While interleukin-6 (IL-6) blockade with monoclonal antibodies is an established, clinically validated mechanism for the treatment of rheumatoid arthritis (RA), the need for significant…
Abstract Number: 1615 • 2016 ACR/ARHP Annual Meeting
Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, Significantly Improves Physical Function and Reduces Morning Stiffness in Patients with Active Rheumatoid Arthritis Despite Anti-TNF Therapy: Results from a Global, Randomized, Placebo-Controlled, Phase 3 Trial
Yoshiya Tanaka¹, Clifton Bingham III², Daniel Aletaha³, Prasheen Agarwal⁴, Sharon Popik⁴, Regina Kurrasch⁵, Steve Peterson⁴, Rita Ganguly⁵, Chenglong Han⁴ and Kelly McQuarrie⁴, ¹University of Occupational and Environmental Health, Kitakyushu, Japan, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵GlaxoSmithKline, Collegeville, PA
Background/Purpose: Improvement in physical function and morning stiffness are key goals of rheumatoid arthritis (RA) treatment. Sirukumab, a selective human anti–IL6 monoclonal antibody, has recently…
Abstract Number: 1625 • 2016 ACR/ARHP Annual Meeting
Analysis of a Phase 3 Study Evaluating the Efficacy of Sirukumab, an Anti-IL-6 Cytokine Monoclonal Antibody, Across Subgroups in Patients with Active Rheumatoid Arthritis Despite Treatment with Disease-Modifying Anti-Rheumatic Drugs
Carter Thorne¹, George Karpouzas², Tsutomu Takeuchi³, Shihong Sheng⁴, Weichun Xu⁴, Ravi Rao⁵, Kaiyin Fei⁴ and Benjamin Hsu⁴, ¹University of Toronto and Southlake Regional Health Centre, Newmarket, ON, Canada, ²Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ³Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom
Background/Purpose: Sirukumab is a human monoclonal antibody that selectively binds to the IL-6 cytokine with high affinity, and is under development for rheumatoid arthritis (RA)…
Abstract Number: 2104 • 2016 ACR/ARHP Annual Meeting
Treatment with Tocilizumab Decreases CXCL13 Expression in Cultured Temporal Arteries from Patients with Giant Cell Arteritis
Nekane Terrades-Garcia¹, Joana Daradoumis², Ester Planas-Rigol², Marc Corbera-Bellalta¹, Sergio Prieto-González², Georgina Espígol-Frigolé² and Maria C. Cid³, ¹Vasculitis Research Unit. Department of Autoimmune Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ²Department of Autoimmune and Systemic Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, ³Autoimmune and Systemic Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain
Background/Purpose: IL-6 has been considered a biomarker of disease activity in GCA and a potential therapeutic target. However, the functional role of IL-6 in GCA…
Abstract Number: 2142 • 2016 ACR/ARHP Annual Meeting
Identification of Novel Molecules Targeting Cartilage Aging As Osteoarthritis Therapeutics
Beatriz Carames¹, Uxia Nogueira-Recalde¹, Eduardo Dominguez², Maria I. Loza³ and Francisco J. Blanco^1,4, ¹Cartilage Biology Group. Rheumatology Division, INIBIC-Hospital Universitario A Coruña, A Coruña, Spain, ²BioFarma Research Group. University of Santiago de Compostela, Santiago de Compostela, Spain, ³BioFarma Research Group. University of Santiago de Compostela, santiago de Compostela, Spain, ⁴Rheumatology Division, INIBIC-Complejo Hospitalario Universitario A Coruña (CHUAC), La Coruña, Spain
Background/Purpose: Effective treatments for Osteoarthritis (OA) are not available. In aging-related diseases, including OA, failure of cellular homeostasis mechanisms, such as autophagy can cause extracellular…
Abstract Number: 2604 • 2016 ACR/ARHP Annual Meeting
Ultrasound and Immunological Changes and Associations after One Year of IL-6/IL- 6R Blockade with Tocilizumab in Rheumatoid Arthritis Patients
Cesar Diaz-Torne¹, Juan Jose De Agustin², Patricia Moya¹, Maria A. Ortiz³, Delia Reina⁴, Carme Moragues⁵, Sergi Ros⁶, Emili Gomez⁷, Enrique Casado Burgos⁸, Eli Garcia⁹, Manel Pujol¹⁰, Maria Pilar Lisbona Perez¹¹, Andrés Ponce¹², V Torrente¹³, P. Estrada¹⁴, Silvia Vidal³ and ECOCAT group, ¹Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, ²Rheumatology, Hospital Baix de Llobregat, Barcelona, Spain, ³Institut de Recerca Sant Pau, Barcelona, Spain, ⁴Rheumatology, Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain, ⁵Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ⁶Rheumatology, Hospital de Viladecans, Viladecans, Spain, ⁷Rheumatology, Hospital Clínic, Barcelona, Spain, ⁸Hospital Universitari Parc Taulí, Sabadell, Spain, ⁹Rheumatology, Hospital de Mollet, Mollet, Spain, ¹⁰Hospital Mútua de Terrassa, Terrassa, Spain, ¹¹Rheumatology, Hospital de Sabadell, Sabadell, Spain, ¹²Rheumatology. Internal Medicine, Hospital General de Granollers, Granollers, Spain, ¹³Hospital de L'Hospitalet, L'Hospitalet de Llobregat, Spain, ¹⁴Rheumatology, Hospital Moises Broggi, Barcelona, Spain
Background/Purpose: Management of RA patients has improved in the last two decades in part with the use of ultrasound (US) in daily clinical practice. The…
Abstract Number: 2620 • 2016 ACR/ARHP Annual Meeting
Retrospective Analysis for Determining the Signs and Symptoms of Infections before They Become Serious in Tocilizumab-Treated RA Patients Using a Postmarketing Adverse Events Reporting Database
Tatsuya Atsumi¹, Yoshiaki Ando², Yukiko Hayashi², Shinichi Matsuda², Riwa Tanaka², Nobuhiro Takagi² and Ayako Nakasone², ¹Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ²Chugai Pharmaceutical Co. Ltd., Tokyo, Japan
Background/Purpose: Given that tocilizumab (TCZ) directly inhibits IL-6 signaling and strongly suppresses the inflammatory reaction, there is concern that the signs and symptoms associated with…
Abstract Number: 2650 • 2016 ACR/ARHP Annual Meeting
Prediction of Inhibition of Radiographic Progression By Sirukumab, an Anti–IL-6 Cytokine Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment: Results of a Global, Phase 3 Trial
George Karpouzas¹, Tsutomu Takeuchi², Carter Thorne³, Shihong Sheng⁴, Xiaoming Li⁴, Ravi Rao⁵, Kaiyin Fei⁴ and Benjamin Hsu⁴, ¹Division of Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ³University of Toronto and Southlake Regional Health Centre, Toronto, ON, Canada, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵GSK Medicines Research Centre, Stevenage, Hertfordshire, United Kingdom
Background/Purpose: In the SIRROUND-D study, sirukumab, a human anti–IL-6 cytokine monoclonal antibody, significantly reduced radiographic progression after 52 wks of treatment vs placebo in patients…
Abstract Number: 249 • 2016 ACR/ARHP Annual Meeting
MiR-204-3p Associates with an Increased Level of IL-6 in Familial Mediterranean Fever By Targeting the PIK3 Signaling Pathway
Tomohiro Koga¹, Kiyoshi Migita², Akihiro Yachie³, Yukitaka Ueki⁴, Kazunaga Agematsu⁵, Junya Masumoto⁶, Koh-ichiro Yoshiura⁷, Katsumi Eguchi⁸ and Atsushi Kawakami¹, ¹Unit of Advanced Preventive Medical Sciences, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Rheumatology and Clinical Research Center, Nagasaki Medical Center, Omura, Japan, ³Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan, ⁴Rheumatic and Collagen Disease Center, Sasebo Chuo Hospital, Sasebo, Japan, ⁵Department of Infectious Immunology, Shinshu University, Graduate School of Medicine, Shinshu, Japan, ⁶Department of Pathology, Division of Analyticalpathology, Ehime University Graduate School of Medicine, Toon, Japan, ⁷Department of Human Genetics, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ⁸Department of Rheumatology and Metabolism, Sasebo City General Hospital, Sasebo, Japan
Background/Purpose: Familial Mediterranean fever (FMF) is caused by a number of mutations of the MEFV gene, coding for a protein named pyrin that acts as…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].